Clinical trials
Advanced clinical trials
Below are recruiting advanced clinical trials, each written for real people, not researchers. We’re tracking 3,897 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06639347RecruitingPhase 1/Phase 2
Testing SHR-A2102 for advanced bladder cancer
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
Guangzhou, GuangdongAges 18 years+ - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT06084286RecruitingPhase 1
CAR-T therapy targeting CLDN18.2 and PD-L1 for advanced solid tumors
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
Chengdu, SichuanAges 18–75 - NCT07636200Recruiting
Managing Fear and Worry in Advanced Cancer
This study tests a new approach to help people with advanced cancer who feel significant fear about their cancer getting worse or coming back. The program uses writing and therapeutic techniques to help reduce this fear and related stress.
Aurora, ColoradoAges 18 years+ - NCT07632365RecruitingPhase 1/Phase 2
Immunotherapy plus chemoradiation for inoperable stage III lung cancer
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
Shanghai, XuhuiAges 18 years+ - NCT07635147Recruiting
Decision Support Tool for Advanced Breast Cancer
This study tests a digital tool designed to help patients with advanced (stage IV) breast cancer make treatment decisions. The tool may help you understand your options and feel more confident discussing them with your doctor.
Brooklyn, New YorkAges 18 years+ - NCT07634380RecruitingPhase 1
Sitagliptin Plus Pembrolizumab for Advanced Kidney or Skin Cancer
This study tests whether adding sitagliptin (a diabetes medication) to pembrolizumab (an immunotherapy) can help patients with advanced kidney cancer or melanoma whose cancer stopped responding to previous immunotherapy treatments. The goal is to see if this combination can shrink tumors and improve survival.
Iowa City, IowaAges 18–99 - NCT06301399RecruitingPhase 2
Rituximab with prior therapy for advanced liver cancer
This trial tests if adding rituximab to previous cancer treatments can help people with advanced hepatocellular carcinoma (a type of liver cancer) that has stopped responding or caused side effects. It aims to see if this combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 17–79 - NCT07622524RecruitingPhase 1
Testing CS5007 for Advanced Solid Tumors
This is an early-stage study testing a new drug called CS5007 in people with advanced cancer that cannot be surgically removed. The goal is to understand how safe the drug is and how well it works.
Darlinghurst, New South WalesAges 18 years+ - NCT07627711RecruitingPhase 1/Phase 2
CAR-NK cells for advanced pancreatic cancer
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
Shenzhen, GuangdongAges 18–75 - NCT07623902Recruiting
Tongue test to improve colorectal cancer screening
This study is testing a new, non-invasive tongue test called Gixam. The goal is to see if the test can help detect colorectal cancer or pre-cancerous growths in people whose standard stool tests (FIT) came back negative, potentially improving screening accuracy.
Mobile, AlabamaAges 45–84 - NCT07629258RecruitingPhase 1
Testing GW01-200 tablets in advanced cancer patients
This is an early-stage trial testing a new drug called GW01-200 in people with advanced solid tumors or blood cancers that have gotten worse despite standard treatment. The study aims to find the right dose and see how well the drug works and is tolerated.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT07619521RecruitingPhase 1/Phase 2
Combination drug therapy for advanced pancreatic cancer
This trial tests two targeted drugs, selumetinib and DS-8201a (trastuzumab deruxtecan), for advanced pancreatic cancer that has spread or cannot be removed. The combination may help people whose tumors have specific markers (KRAS mutation and HER2 positivity).
New Haven, ConnecticutAges 18 years+ - NCT07617727RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
Fuzhou, FujianAges 18–75 - NCT07618260RecruitingPhase 1
Testing SIM0613 in advanced solid tumors
This is an early-stage trial testing a new drug called SIM0613 for advanced cancers that have spread or grown despite other treatments. The drug is designed to target cancer cells using a special delivery system.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07612891RecruitingPhase 1/Phase 2
Testing INV-6452 for advanced breast cancer and solid tumors
This study tests a new drug called INV-6452 to see if it is safe and can help control advanced cancers that have grown despite prior treatment. The drug targets specific cancer cell weaknesses, particularly in hormone-sensitive breast cancers without HER2 mutations.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07617493RecruitingPhase 1/Phase 2
ICP-B208 for Advanced Solid Tumors
This early-stage trial tests a new cancer drug called ICP-B208 in people with advanced solid tumors (like stomach, colon, or other cancers) that have spread or cannot be removed surgically and have not responded to previous treatments. The study aims to find the right dose and see how well the drug works.
Beijing, Beijing MunicipalityAges 18–75 - NCT06708858RecruitingPhase 2
Studying surufatinib with chemo and immunotherapy for advanced bile duct cancer
This trial tests a combination of a targeted therapy (surufatinib), chemotherapy (gemcitabine and cisplatin), and an immunotherapy (durvalumab or pembrolizumab) for people with advanced bile duct cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07605962RecruitingPhase 1/Phase 2
UI-102 treatment for advanced cancer
This early-stage trial tests a new drug called UI-102 in people with advanced cancer. Researchers want to see if it is safe and whether it can help shrink tumors in patients who have already tried standard treatments.
Dallas, TexasAges 18 years+ - NCT07607678RecruitingPhase 1
Testing BI 3819026 Alone and With Ezabenlimab for Advanced Cancer
This early-stage study tests whether a new drug called BI 3819026, alone or combined with another drug called ezabenlimab, is safe and well-tolerated in people whose advanced solid tumors have stopped responding to standard treatments. The goal is to find the right dose and understand how the drugs work in your body.
New Haven, ConnecticutAges 18 years+ - NCT07604571RecruitingPhase 1
Testing IEV407 for Advanced Hormone-Sensitive Breast Cancer
This study tests a new drug called IEV407, either alone or combined with existing hormone therapies, in people with advanced breast cancer that is hormone-receptor positive and HER2 negative. The trial aims to find the right dose and see if this combination helps people whose cancer has stopped responding to previous treatments.
New Haven, ConnecticutAges 18 years+ - NCT07607054RecruitingPhase 1
EMB-15 for advanced solid tumors without standard treatment
This is a first-time-in-humans study testing a new drug called EMB-15 for patients with advanced cancers that have spread or cannot be surgically removed. The drug targets proteins called ALPP/ALPG, which may help your immune system fight cancer cells.
Guangzhou, GuangdongAges 18 years+
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced?
- Yes. Clin2 currently lists 3,897 recruiting advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.